A New Hypoxia-Related Prognostic Risk Score (HPRS) Model Was Developed to Indicate Prognosis and Response to Immunotherapy for Lung Adenocarcinoma

Figure 3

Establishment and validation of HPRS for predicting the prognosis of LUAD. (a): Univariate Cox regression analysis of genes in pink module and LUAD survival. (b): The cross-validation for penalty parameter λ selection in the LASSO regression. (c): Partial likelihood deviance for the LASSO coefficient profile. (d): The LASSO Cox coefficients of 5 hypoxia-related genes. (e): The relationship between the arrangement of HPRS of each LUAD patient in TCGA and patient survival and the expression of 5 genes. (f): ROC curve and AUC of 1-, 3-, and 5-year survival in TCGA. (g): The survival curve of LUAD patients with high HPRS and patients with low HPRS in TCGA. (h): The AUC for 1-year, 3-year, and 5-year ROC in external validation set. (i): Survival analysis of patients with different HPRS in external validation set GSE31210. (j): The sensitivity and specificity of ROC curve in predicting 1-, 3-, and 5-year survival in GSE50081. (k): Kaplan–Meier curve of patients with different HPRS in GSE50081.